短效与长效GLP-1受体激动剂联合基础胰岛素治疗2型糖尿病的疗效与安全性荟萃分析
该荟萃分析纳入14项随机对照试验,比较短效与长效GLP-1受体激动剂联合基础胰岛素治疗2型糖尿病的疗效与安全性。结果显示,长效GLP-1受体激动剂在降低HbA1c、空腹血糖和体重方面更有效,且症状性低血糖和恶心呕吐发生率更低。
要点
- 长效GLP-1 RA联合基础胰岛素降HbA1c、空腹血糖和体重优于短效。
- 长效GLP-1 RA的症状性低血糖发生率更低,但严重低血糖无差异。
- 长效GLP-1 RA的恶心和呕吐发生率显著低于短效。
核心结论
- 长效GLP-1受体激动剂联合基础胰岛素在血糖控制和体重管理上优于短效,且胃肠道耐受性更好。
研究设计与样本
- 荟萃分析纳入14项随机对照试验,比较短效或长效GLP-1受体激动剂联合基础胰岛素与基础胰岛素±安慰剂。
- 8项试验使用短效GLP-1受体激动剂,6项使用长效GLP-1受体激动剂。
- 采用随机效应模型比较HbA1c、空腹血糖、体重和不良事件差异。
主要发现
- 长效相比短效GLP-1受体激动剂进一步降低HbA1c:∆ -6 mmol/mol(95% CI -10; -2),P=0.007。
- 长效相比短效进一步降低空腹血糖:∆ -0.7 mmol/L(95% CI -1.2; -0.3),P=0.007。
- 长效相比短效进一步降低体重:∆ -1.4 kg(95% CI -2.2; -0.6),P=0.002。
- 长效GLP-1受体激动剂达到HbA1c<7.0%(<53 mmol/mol)的患者比例更高(P=0.03)。
- 长效GLP-1受体激动剂症状性低血糖更少(P=0.048),严重低血糖无差异(P=0.96)。
临床怎么用
- 在基础胰岛素治疗基础上,优先选择长效GLP-1受体激动剂以优化血糖和体重控制。
- 长效GLP-1受体激动剂可能减少症状性低血糖和胃肠道不良反应风险。
局限性
- 可用的文献数量相对较少。
- 研究方案存在一定异质性。
- 使用的GLP-1受体激动剂化合物存在差异。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To compare the efficacy and safety of short- and long-acting glucagon-like peptide 1 receptor agonists (GLP-1 RAs), both used in combination with basal insulin, in patients with type 2 diabetes. DATA SOURCES AND STUDY SELECTION: Randomized controlled trials comparing the coadministration of short- or long-acting GLP-1 RAs and basal insulin with basal insulin ± placebo were identified (PubMed search). Of 974 identified publications, 14 clinical trials were included. Eight trials examined short-acting and six long-acting GLP-1 RAs. DATA EXTRACTION AND DATA SYNTHESIS: Differences in HbA1c, fasting plasma glucose, body weight, and adverse events were compared between studies using short- or long-acting GLP-1 RAs by random-effects meta-analysis. LIMITATIONS: There were relatively small numbers of available publications, some heterogeneity regarding protocols, and differences in the GLP-1 RA compound used. CONCLUSIONS: Long-acting GLP-1 RAs more effectively reduced HbA1c (∆ -6 mmol/mol [95% CI -10; -2], P = 0.007), fasting plasma glucose (∆ -0.7 mmol/L [-1.2; -0.3], P = 0.007), and body weight (∆ -1.4 kg [-2.2; -0.6], P = 0.002) and raised the proportion of patients achieving an HbA1c target <7.0% (<53 mmol/mol) (P = 0.03) more than the short-acting ones. Patients reporting symptomatic (P = 0.048) but not severe (P = 0.96) hypoglycemia were fewer with long- versus short-acting GLP-1 RAs added to insulin. A lower proportion of patients reported nausea (-52%, P < 0.0001) or vomiting (-36%, P = 0.0002) with long-acting GLP-1 RAs. Overall, GLP-1 RAs improved HbA1c, fasting plasma glucose, and body weight when added to basal insulin. However, long-acting GLP-1 RAs were significantly more effective for glycemic and body weight control and displayed better gastrointestinal tolerability.
引用
- Huthmacher JA, Meier JJ, Nauck MA, et al. Efficacy and Safety of Short- and Long-Acting Glucagon-Like Peptide 1 Receptor Agonists on a Background of Basal Insulin in Type 2 Diabetes: A Meta-analysis. Diabetes Care. 2020. PMID: 32910778. doi:10.2337/dc20-0498
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。